Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluate the Efficacy and Safety of ARX788 in Patients With HER2-positive Advanced Breast Cancer Whose Disease Has Progressed Following T-DXd Therapy

NCT06578286 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06578286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06578286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluate the Efficacy and Safety of ARX788 in Patients With HER2-positive Advanced Breast Cancer Whose Disease Has Progressed Following T-DXd Therapy
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2024
Completion date
September 30, 2030
Enrollment
44 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer